^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Thyroid Gland Medullary Carcinoma |
| Drug: | Cometriq (cabozantinib capsule) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer
Excerpt:
...mutational status of codons 12, 13, and 61 in KRAS, NRAS, and HRAS…cabozantinib provides the greatest clinical benefit to patients with MTC who have RET M918T or RAS mutations.
DOI:
10.1002/cncr.30252
Trial ID:
